Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 270,955
  • Shares Outstanding, K 54,191
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,730 K
  • EBIT $ -75 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.12
  • Price/Sales 770.36
  • Price/Cash Flow N/A
  • Price/Book 1.61

Options Overview Details

View History
  • Implied Volatility 82.09% (-6.48%)
  • Historical Volatility 79.56%
  • IV Percentile 4%
  • IV Rank 3.79%
  • IV High 899.87% on 11/28/25
  • IV Low 49.91% on 01/22/25
  • Expected Move (DTE 2) 0.21 (4.25%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 499
  • Volume Avg (30-Day) 2,048
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 82,842
  • Open Int (30-Day) 76,712
  • Expected Range 4.79 to 5.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.42
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +20.19%
on 11/20/25
5.61 -10.79%
on 12/10/25
+0.55 (+12.36%)
since 11/14/25
3-Month
4.00 +25.00%
on 11/07/25
5.82 -14.09%
on 09/17/25
-0.68 (-11.97%)
since 09/16/25
52-Week
3.93 +27.23%
on 04/09/25
7.54 -33.69%
on 08/15/25
-0.89 (-15.11%)
since 12/16/24

Most Recent Stories

More News
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind,...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics: Q3 Earnings Snapshot

Abeona Therapeutics: Q3 Earnings Snapshot

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

- First anticipated ZEVASKYN ® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced...

ABEO : 5.00 (-1.57%)
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced...

ABEO : 5.00 (-1.57%)

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 5.22
2nd Resistance Point 5.17
1st Resistance Point 5.09
Last Price 5.00
1st Support Level 4.96
2nd Support Level 4.91
3rd Support Level 4.83

See More

52-Week High 7.54
Fibonacci 61.8% 6.16
Fibonacci 50% 5.74
Fibonacci 38.2% 5.31
Last Price 5.00
52-Week Low 3.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar